Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Reports from S.M. Gressett and co-researchers add new data to research in angiogenesis
May 5th, 2009
According to a study from the United States, "To review the serious and common toxicities of bevacizumab and describe their incidence, risk factors, presentation, pathophysiology, and management. Literature for this review article was collected from PubMed, MEDLINE, and the proceedings of the American Society of Clinical Oncology (2000-November 2008)." "The key terms used in the search were: bevacizumab, vascular endothelial growth factor, angiogenesis inhibitors, toxicity, toxicity management, and adverse event. AND DATA EXTRACTION: Review articles, preclinical studies, and all published Phase 1-3 clinical trials were reviewed. The references listed in identified...
Source: Cancer Weekly (2009-05-05)
|
